[1] Curl WW, Krome J, Gordon ES, et al. Cartilage injuries: a review of 31,516 knee arthroscopies. Arthroscopy. 1997;13(4): 456-460.[2] Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58(1): 26-35.[3] Capeci CM, Turchiano M, Strauss EJ, et al. Osteochondral allografts: applications in treating articular cartilage defects in the knee. Bull Hosp Jt Dis (2013). 2013; 71(1): 60-67.[4] Clouet J, Vinatier C, Merceron C, et al. From osteoarthritis treatments to future regenerative therapies for cartilage. Drug Discov Today. 2009; 14(19-20): 913-925.[5] Johnson K, Zhu S, Tremblay MS, et al. A stem cell-based approach to cartilage repair. Science. 2012;336(6082): 717-721.[6] Jackson MT, Moradi B, Smith MM, et al. Activation of matrix metalloproteinases 2, 9, and 13 by activated protein C in human osteoarthritic cartilage chondrocytes. Arthritis Rheumatol. 2014;66(6): 1525-1536.[7] Lipari L, Gerbino A. Expression of gelatinases (MMP-2, MMP-9) in human articular cartilage. Int J Immunopathol Pharmacol. 2013;26(3): 817-823.[8] Alves AC, Albertini R, dos SSA, et al. Effect of low-level laser therapy on metalloproteinase MMP-2 and MMP-9 production and percentage of collagen types I and III in a papain cartilage injury model. Lasers Med Sci. 2014;29(3): 911-919.[9] Vo N, Niedernhofer LJ, Nasto LA, et al. An overview of underlying causes and animal models for the study of age-related degenerative disorders of the spine and synovial joints. J Orthop Res. 2013;31(6): 831-837.[10] Komarek J, Valis P, Repko M, et al. Treatment of deep cartilage defects of the knee with autologous chondrocyte transplantation: long-term results. Acta Chir Orthop Traumatol Cech. 2010;77(4): 291-295.[11] Martin JA, Klingelhutz AJ, Moussavi-Harami F, et al. Effects of oxidative damage and telomerase activity on human articular cartilage chondrocyte senescence. J Gerontol A Biol Sci Med Sci. 2004;59(4): 324-337.[12] Place ES, Nair R, Chia HN, et al. Latent TGF-beta hydrogels for cartilage tissue engineering. Adv Healthc Mater. 2012;1(4): 480-484.[13] Falsafi S, Koch RJ. Growth of tissue-engineered human nasoseptal cartilage in simulated microgravity. Arch Otolaryngol Head Neck Surg. 2000;126(6): 759-765.[14] Lim HC, Bae JH, Song SH, et al. Current treatments of isolated articular cartilage lesions of the knee achieve similar outcomes. Clin Orthop Relat Res. 2012;470(8): 2261-2267.[15] Hayek A, Kerstetter-Fogle AE, Sachlos E, et al. Kartogenin: a game-changer in regenerative medicine. Regen Med. 2012;7(4): 475.[16] Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11: 529-543.[17] Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013;146(3): 185-196.[18] Gargiulo S, Gamba P, Poli G, et al. Metalloproteinases and metalloproteinase inhibitors in age-related diseases. Curr Pharm Des. 2014;20(18): 2993-3018.[19] Shi D, Xu X, Ye Y, et al. Photo-Cross-Linked Scaffold with Kartogenin-Encapsulated Nanoparticles for Cartilage Regeneration. ACS Nano. 2016;10(1): 1292-1299.[20] Liu C, Ma X, Li T, et al. Kartogenin, transforming growth factor-beta1 and bone morphogenetic protein-7 coordinately enhance lubricin accumulation in bone-derived mesenchymal stem cells. Cell Biol Int. 2015;39(9): 1026-1035.[21] Kang ML, Ko JY, Kim JE, et al. Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration. Biomaterials. 2014;35(37): 9984-9994.[22] Jackson MT, Moradi B, Smith MM, et al. Activation of matrix metalloproteinases 2, 9, and 13 by activated protein C in human osteoarthritic cartilage chondrocytes. Arthritis Rheumatol. 2014;66(6): 1525-1536.[23] Zeng GQ, Chen AB, Li W, et al. High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis. Genet Mol Res. 2015;14(4): 14811-14822. |